This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
necrosis factor | 975 |
immune response | 919 |
mg kg | 812 |
immune system | 800 |
dendritic cells | 779 |
cell line | 779 |
inflammatory cytokines | 772 |
endothelial cells | 770 |
gene expression | 757 |
peripheral blood | 738 |
cell lines | 718 |
nk cells | 683 |
tumor necrosis | 682 |
inflammatory response | 668 |
cell death | 629 |
immune responses | 617 |
flow cytometry | 602 |
ng ml | 562 |
present study | 530 |
nitric oxide | 528 |
control group | 525 |
important role | 515 |
cell proliferation | 506 |
significantly higher | 503 |
growth factor | 492 |
amino acid | 487 |
type i | 484 |
septic shock | 475 |
lymph nodes | 475 |
pg ml | 468 |
cytokine production | 450 |
mononuclear cells | 441 |
results suggest | 428 |
innate immune | 424 |
mrna expression | 413 |
mbl levels | 406 |
healthy controls | 386 |
bone marrow | 377 |
oxidative stress | 370 |
cancer cell | 363 |
adhesion molecules | 354 |
blood samples | 349 |
significantly increased | 347 |
breast cancer | 346 |
lung injury | 346 |
epithelial cells | 346 |
blood mononuclear | 330 |
results indicate | 328 |
intensive care | 319 |
tumour necrosis | 313 |
rheumatoid arthritis | 310 |
cancer cells | 303 |
acute respiratory | 296 |
endothelial cell | 296 |
complement activation | 294 |
immune cells | 293 |
cell surface | 286 |
multiple sclerosis | 286 |
transcription factor | 284 |
class ii | 283 |
cell activation | 275 |
cell types | 275 |
iga protease | 273 |
binding lectin | 272 |
cell responses | 270 |
blood flow | 268 |
inflammatory cytokine | 267 |
type ii | 256 |
cd cd | 254 |
clinical signs | 253 |
blood pressure | 251 |
ex vivo | 250 |
proinflammatory cytokines | 248 |
class i | 248 |
statistically significant | 248 |
protein kinase | 247 |
significant increase | 247 |
cell cycle | 246 |
inflammatory mediators | 245 |
smooth muscle | 245 |
high levels | 242 |
iga antibody | 240 |
monoclonal antibody | 239 |
time pcr | 237 |
nervous system | 236 |
whole blood | 236 |
data suggest | 233 |
inflammatory responses | 232 |
western blot | 231 |
cd expression | 228 |
organ failure | 227 |
increased levels | 226 |
signal transduction | 226 |
ms patients | 226 |
influenza virus | 225 |
mrna levels | 223 |
protein expression | 220 |
serum levels | 220 |
spinal cord | 218 |
natural killer | 217 |
activated macrophages | 217 |
dependent manner | 217 |
mouse model | 215 |
virus infection | 213 |
significantly lower | 212 |
vascular endothelial | 211 |
cellular immune | 209 |
like domain | 209 |
chronic inflammatory | 208 |
significantly reduced | 205 |
inflammatory diseases | 204 |
critically ill | 202 |
acute lung | 201 |
significant difference | 200 |
blood donors | 199 |
viral infection | 198 |
significant differences | 197 |
herpes simplex | 197 |
reactive oxygen | 197 |
cytokine storm | 196 |
patients receiving | 193 |
clinical trials | 192 |
type diabetes | 192 |
results showed | 191 |
respiratory syndrome | 190 |
mechanical ventilation | 190 |
stem cells | 188 |
cells may | 186 |
specific cd | 186 |
signaling pathway | 185 |
time points | 185 |
healthy individuals | 184 |
simplex virus | 184 |
lactic acid | 182 |
signaling pathways | 182 |
critical role | 182 |
may play | 181 |
acute phase | 181 |
innate immunity | 180 |
binding site | 180 |
may also | 180 |
multiple organ | 178 |
two groups | 177 |
oral mucosa | 177 |
performed using | 177 |
tumour cells | 177 |
proliferating cells | 176 |
severe acute | 176 |
alternatively activated | 175 |
adaptive immunity | 175 |
colorectal cancer | 174 |
monoclonal antibodies | 174 |
cell response | 172 |
pivotal role | 171 |
transcription factors | 171 |
central nervous | 171 |
human collectins | 171 |
pattern recognition | 171 |
autoimmune diseases | 170 |
mast cells | 170 |
respiratory distress | 170 |
acid bacteria | 169 |
genes involved | 169 |
tumor cells | 169 |
pregnant women | 168 |
wild type | 168 |
mg ml | 168 |
lectin pathway | 167 |
adhesion molecule | 165 |
like receptor | 163 |
plasma levels | 163 |
may contribute | 162 |
animal models | 162 |
side effects | 161 |
blood cells | 160 |
oxygen species | 160 |
mhc i | 159 |
mhc class | 159 |
recent studies | 158 |
distress syndrome | 158 |
deficient mice | 158 |
cell adhesion | 156 |
macrophage activation | 156 |
small intestine | 155 |
inflammatory bowel | 154 |
plasma membrane | 154 |
doc id | 153 |
cord uid | 153 |
expression levels | 152 |
inflammatory effects | 151 |
peritoneal macrophages | 150 |
molecular mechanisms | 150 |
taken together | 150 |
western blotting | 150 |
determine whether | 149 |
protease activity | 149 |
fatty acids | 149 |
stem cell | 148 |
adipose tissue | 148 |
ill patients | 148 |
commercially available | 147 |
may therefore | 147 |
activated protein | 147 |
binding assays | 146 |
surface expression | 145 |
amino acids | 145 |
body weight | 145 |
healthy volunteers | 145 |
mice immunized | 144 |
ear skin | 143 |
risk factors | 143 |
protective effect | 143 |
i molecules | 142 |
results demonstrate | 142 |
cancer patients | 142 |
previous studies | 142 |
higher levels | 142 |
clinical trial | 141 |
gut flora | 141 |
patients compared | 141 |
increased expression | 141 |
escherichia coli | 141 |
increased risk | 141 |
significantly decreased | 141 |
antiviral activity | 140 |
th cells | 140 |
growth factors | 140 |
findings suggest | 140 |
inflammatory cells | 140 |
molecular weight | 139 |
receptor antagonist | 139 |
dc maturation | 139 |
apoptotic cells | 139 |
statistical analysis | 138 |
control donors | 138 |
bowel disease | 138 |
autologous bacteria | 138 |
small intestinal | 138 |
humoural responses | 137 |
proteome analysis | 137 |
tnf production | 137 |
viral infections | 137 |
epithelial cell | 137 |
peptide antigens | 137 |
healthy donors | 136 |
corresponding hc | 136 |
high mbl | 136 |
alveolar macrophages | 136 |
lactobacillus spp | 136 |
recombinant human | 135 |
receptor expression | 135 |
major role | 135 |
host defense | 134 |
gestational age | 134 |
cd cells | 134 |
ifn species | 134 |
care unit | 134 |
oxide synthase | 134 |
systemic lupus | 134 |
insulin resistance | 133 |
intracellular ifn | 133 |
cardiac output | 133 |
cell subsets | 133 |
lymph node | 133 |
human blood | 133 |
proinflammatory cytokine | 132 |
like receptors | 132 |
sentinel lymph | 132 |
lactobacillus acidophilus | 132 |
related lipoproteins | 132 |
white blood | 131 |
endothelial growth | 131 |
transforming growth | 131 |
preliminary results | 131 |
lupus erythematosus | 130 |
septic patients | 130 |
target cells | 129 |
infected cells | 129 |
reperfusion injury | 129 |
university hospital | 128 |
severe covid | 128 |
binding protein | 128 |
negative bacteria | 127 |
findings indicate | 127 |
clinical use | 127 |
surface markers | 126 |
infected mice | 126 |
blot analysis | 125 |
mast cell | 125 |
heat shock | 125 |
binding proteins | 125 |
specific antibodies | 125 |
airway inflammation | 124 |
patienten mit | 124 |
analysed using | 123 |
viral replication | 123 |
cell type | 123 |
vitro stimulation | 123 |
may provide | 122 |
risk factor | 121 |
sequence homology | 121 |
ko mice | 121 |
human peripheral | 121 |
bronchial asthma | 120 |
nuclear factor | 120 |
complement system | 120 |
th th | 120 |
myocardial infarction | 120 |
systemic inflammatory | 120 |
factor alpha | 120 |
disease activity | 120 |
fish oil | 120 |
beneficial effects | 119 |
mean age | 119 |
disease severity | 119 |
dna damage | 119 |
control animals | 118 |
mass spectrometry | 118 |
type ifn | 118 |
heart failure | 118 |
adaptive immune | 117 |
dna vaccine | 117 |
healthy blood | 117 |
cytokine profile | 117 |
cytokine levels | 117 |
human recombinant | 117 |
severe sepsis | 116 |
key role | 116 |
regression analysis | 116 |
cell function | 116 |
currently investigating | 116 |
also found | 115 |
organ dysfunction | 115 |
nk cell | 115 |
cell culture | 115 |
cytokines il | 115 |
central role | 114 |
serine proteases | 114 |
cell cytotoxicity | 114 |
results will | 114 |
two different | 114 |
normal human | 113 |
single nucleotide | 113 |
may help | 113 |
protein levels | 113 |
sendai virus | 112 |
tumour cell | 112 |
heart rate | 112 |
lower levels | 111 |
weight loss | 111 |
results show | 111 |
allergic rhinitis | 111 |
presenting cells | 110 |
cell count | 110 |
cell growth | 110 |
cell cultures | 109 |
first time | 108 |
th phenotype | 108 |
cell viability | 108 |
cell receptor | 108 |
inhibitory effect | 108 |
cell migration | 108 |
serine protease | 107 |
positive cells | 107 |
antigen presentation | 107 |
human monocytes | 107 |
response towards | 107 |
converting enzyme | 106 |
data indicate | 106 |
dna vaccination | 106 |
pss patients | 106 |
normal mucosa | 105 |
complement activity | 105 |
extracellular matrix | 105 |
iga antibodies | 105 |
muscle cells | 105 |
lipid peroxidation | 105 |
staphylococcus aureus | 104 |
fatty acid | 104 |
wound healing | 104 |
inflammatory disease | 104 |
special emphasis | 104 |
pulmonary artery | 104 |
stranded rna | 104 |
dairy cows | 103 |
target bacteria | 103 |
clonally expanded | 103 |
oral carcinoma | 103 |
high concentrations | 103 |
mg dl | 103 |
bioinformatics tools | 103 |
macrophage galactose | 102 |
induced apoptosis | 102 |
weak il | 102 |
mbl genotypes | 102 |
cytokine responses | 102 |
mbl double | 102 |
ectopic gc | 102 |
virus type | 102 |
serum mbl | 102 |
protein level | 102 |
reactive protein | 102 |
nkt cells | 101 |
acid residues | 101 |
protein synthesis | 101 |
plasmodium falciparum | 101 |
renal failure | 101 |
binding regions | 101 |
cytokine tumour | 101 |
differentially expressed | 101 |
mammalian cells | 100 |
global proteome | 100 |
arachidonic acid | 100 |
protein microarrays | 100 |
bacteria lactobacillus | 99 |
antibody microarrays | 99 |
immune complexes | 99 |
venous blood | 99 |
apoptotic cell | 99 |
cell reactivity | 99 |
database system | 99 |
hla supertypes | 99 |
ml kg | 99 |
diabetes mellitus | 99 |
different time | 99 |
transduced eph | 99 |
bacterial antigen | 99 |
mbl masp | 99 |
apache ii | 98 |
previously shown | 98 |
fusion proteins | 98 |
skeletal muscle | 97 |
clinical studies | 97 |
superoxide dismutase | 97 |
may cause | 97 |
tnf receptor | 96 |
colon cancer | 96 |
fusion protein | 96 |
using flow | 96 |
previously reported | 96 |
acute pancreatitis | 95 |
group i | 95 |
significantly elevated | 95 |
gastrointestinal tract | 95 |
fold increase | 95 |
transgenic mice | 95 |
tissue damage | 95 |
control subjects | 94 |
gel electrophoresis | 94 |
low levels | 94 |
nucleotide polymorphisms | 94 |
large intestine | 94 |
cytokine response | 94 |
long term | 93 |
cell differentiation | 93 |
normal subjects | 93 |
significantly associated | 92 |
cardiovascular disease | 92 |
significantly different | 92 |
killer cell | 92 |
body mass | 92 |
recently identified | 92 |
may result | 92 |
may lead | 92 |
possible role | 92 |
years old | 92 |
cell survival | 92 |
studies will | 91 |
negative feedback | 91 |
human lung | 91 |
cells showed | 90 |
mechanisms underlying | 90 |
two patients | 90 |
three different | 90 |
infected patients | 90 |
stimulating factor | 90 |
trauma patients | 90 |
respiratory tract | 90 |
control groups | 89 |
chronic inflammation | 89 |
fold higher | 89 |
analysis revealed | 89 |
crucial role | 89 |
may occur | 89 |
recognition receptors | 89 |
protein content | 88 |
arterial blood | 88 |
ca i | 88 |
arterial pressure | 88 |
cytokine release | 88 |
measured using | 88 |
significant decrease | 88 |
factor receptor | 88 |
immunized mice | 88 |
i ifn | 88 |
tissue factor | 87 |
high amounts | 87 |
mortality rate | 87 |
ra patients | 87 |
igg antibodies | 87 |
assay using | 86 |
cancer treatment | 86 |
er stress | 86 |
animal model | 86 |
activating factor | 86 |
large number | 86 |
allergic airway | 86 |
patients presented | 85 |
carcinoma cell | 85 |
infl ammatory | 85 |
significant reduction | 85 |
real time | 85 |
autoimmune disease | 85 |
increased significantly | 85 |
falciparum malaria | 84 |
respiratory failure | 84 |
less pronounced | 84 |
icu patients | 84 |
lung tissue | 84 |
wt mice | 84 |
survival rate | 84 |
systemic inflammation | 83 |
human il | 83 |
bladder cancer | 83 |
induced release | 83 |
widely used | 83 |
cd ra | 83 |
kg day | 83 |
major source | 82 |
cord injury | 82 |
human monoclonal | 82 |
one study | 82 |
closely related | 82 |
endoplasmic reticulum | 82 |
antibodies specific | 82 |
response syndrome | 82 |
one may | 82 |
cells express | 81 |
cell epitopes | 81 |
free radicals | 81 |
brain injury | 81 |
treatment group | 81 |
bl mice | 81 |
serum samples | 81 |
first trimester | 81 |
amniotic fluid | 81 |
complement components | 81 |
tissue injury | 81 |
increased production | 80 |
weeks post | 80 |
medical center | 80 |
vascular resistance | 80 |
serum albumin | 80 |
effector cells | 79 |
will allow | 79 |
lung inflammation | 79 |
tumor cell | 79 |
ang ii | 79 |
crystal structure | 79 |
cells within | 79 |
plasma cells | 79 |
type cytokines | 79 |
dose dependent | 79 |
ml min | 79 |
psoriatic skin | 78 |
cytokine secretion | 78 |
investigated whether | 78 |
expression pattern | 78 |
naturally occurring | 78 |
regional lymph | 77 |
vitro studies | 77 |
also known | 77 |
promoter region | 77 |
previously described | 77 |
induced il | 77 |
subsequent development | 77 |
vascular endothelium | 77 |
syndrome coronavirus | 77 |
molecular markers | 77 |
cysteine protease | 77 |
coli lps | 77 |
murine model | 77 |
cell apoptosis | 77 |
lung cancer | 77 |
high risk | 77 |
virus replication | 76 |
related molecules | 76 |
diabetic patients | 76 |
poor prognosis | 76 |
single amino | 76 |
i ifns | 76 |
patients showed | 76 |
terminal part | 76 |
peritoneal fluid | 76 |
liver injury | 76 |
experimental autoimmune | 76 |
total rna | 76 |
large amounts | 76 |
acute myocardial | 75 |
investigate whether | 75 |
large colon | 75 |
elevated levels | 75 |
cell layer | 75 |
fas ligand | 75 |
mice compared | 75 |
fetal growth | 75 |
inflammatory process | 75 |
current study | 74 |
derived peptides | 74 |
cd bright | 74 |
feedback regulation | 74 |
mesenchymal stem | 74 |
infectious diseases | 74 |
expression profiles | 74 |
found among | 74 |
induced arthritis | 74 |
vascular permeability | 74 |
myeloid cells | 74 |
produce il | 74 |
logistic regression | 74 |
costimulatory molecule | 74 |
marginal zone | 74 |
mouse models | 74 |
major histocompatibility | 74 |
linked immunosorbent | 74 |
coronavirus disease | 73 |
plasma samples | 73 |
nonstructural protein | 73 |
biological activity | 73 |
map kinase | 73 |
analyzed using | 73 |
mediated immunity | 73 |
maturation markers | 73 |
cells decreased | 73 |
high dose | 73 |
human gut | 73 |
monitor patients | 73 |
high affinity | 73 |
tyrosine kinase | 73 |
future studies | 73 |
peptide ligands | 72 |
dust mite | 72 |
therapeutic approach | 72 |
also may | 72 |
patients treated | 72 |
knockout mice | 72 |
vascular complications | 72 |
wide range | 72 |
hydrogen peroxide | 72 |
activation state | 72 |
th response | 72 |
flow cytometric | 72 |
acid substitution | 72 |
lcm virus | 71 |
predisposing factor | 71 |
autoimmune encephalomyelitis | 71 |
ko animals | 71 |
pylori infection | 71 |
dietary vitamin | 71 |
increasingly used | 71 |
specific cytotoxic | 71 |
several studies | 71 |
showed increased | 71 |
postoperative infections | 71 |
protective effects | 71 |
large panel | 71 |
respiratory syncytial | 71 |
ischemia reperfusion | 71 |
blood cell | 71 |
rat model | 71 |
cardiogenic shock | 71 |
first step | 70 |
release assay | 70 |
activate nk | 70 |
immunomodulatory therapies | 70 |
critical care | 70 |
lactobacillus rhamnosus | 70 |
model system | 70 |
gastric juice | 70 |
lg ml | 70 |
bacterial strains | 70 |
patients without | 70 |
splenic cd | 70 |
induced rantes | 70 |
peptides spanning | 70 |
carcinoma cells | 70 |
culture supernatants | 70 |
positive correlation | 70 |
commensal bacteria | 70 |
rantes expression | 70 |
immune cell | 70 |
currently trying | 70 |
dm patients | 70 |
cytokine environment | 70 |
antibody fragments | 70 |
ii cytokine | 70 |
adaptor molecules | 70 |
within hours | 69 |
membrane depolarization | 69 |
virus nonstructural | 69 |
children living | 69 |
eae induction | 69 |
syncytial virus | 69 |
contact sensitivity | 69 |
protein microarray | 69 |
cell membrane | 69 |
dna construct | 69 |
focus score | 69 |
ctl activity | 69 |
mt mt | 69 |
quantitative real | 69 |
soluble vascular | 69 |
solid supports | 69 |
inducible nitric | 69 |
tlr adaptor | 69 |
macrovascular complications | 69 |
recall stimulation | 69 |
type mice | 69 |
colon mucosa | 69 |
mt cells | 69 |
peptide mapping | 69 |
responsiveness ex | 68 |
pathological conditions | 68 |
type lectins | 68 |
allergic asthma | 68 |
may influence | 68 |
specific immune | 68 |
reactive lymphocytes | 68 |
ingested probiotics | 68 |
associated serine | 68 |
genes encoding | 68 |
pneumoniae serotypes | 68 |
oligoadenylate synthetases | 68 |
noise threshold | 68 |
bifidobacterium spp | 68 |
novel markers | 68 |
hydrophobic interaction | 68 |
low tnf | 68 |
immature dcs | 68 |
pressurized chamber | 68 |
aureus serotypes | 68 |
human mnsod | 68 |
programmed cell | 68 |
double ko | 68 |
fluticasone propionate | 68 |
tcr vb | 68 |
pylori igg | 68 |
rhamnosus gg | 68 |
laboratory information | 68 |
mbl ko | 68 |
mt phenotype | 68 |
cytotoxicity increased | 68 |
normoalbuminuric group | 68 |
derived macrophages | 68 |
histocompatibility complex | 68 |
bronchoalveolar lavage | 68 |
including ingested | 68 |
will address | 68 |
potentially immunogenic | 68 |
igg caga | 68 |
mbl gene | 68 |
persons working | 68 |
macrophage inflammatory | 68 |
sows fed | 68 |
protected rats | 68 |
five putative | 68 |
hyperbaric exposure | 68 |
patients undergoing | 68 |
protease inhibitor | 68 |
chain reaction | 68 |
ics alone | 68 |
mt ratio | 68 |
malarial antigen | 68 |
immune status | 68 |
seroimmunological phenotype | 68 |
normal colon | 68 |
final visit | 68 |
ifn biologicals | 67 |
titrations making | 67 |
i interferon | 67 |
interaction chromatography | 67 |
serum resistance | 67 |
birth weight | 67 |
versus mg | 67 |
better reporter | 67 |
times higher | 67 |
mammary gland | 67 |
standard operating | 67 |
adverse effects | 67 |
laborious titrations | 67 |
assays require | 67 |
gene products | 67 |
cell population | 67 |
intercellular contact | 67 |
require laborious | 67 |
protease domains | 67 |
induces apoptosis | 67 |
carried using | 67 |
ae sem | 67 |
micro flora | 67 |
inducible costimulator | 67 |
scale clinical | 67 |
zinc deficiency | 67 |
predicted binding | 67 |
activate complement | 67 |
recognition molecules | 67 |
unique possibility | 67 |
bioavailability varies | 67 |
antiviral neutralization | 67 |
bacterial stimulation | 67 |
mbp antibodies | 67 |
one patient | 67 |
determined using | 67 |
induced complement | 67 |
derived antigens | 67 |
hyperimmunized mice | 66 |
svegfr concentrations | 66 |
operating procedures | 66 |
recognition molecule | 66 |
qbc experiment | 66 |
mbl pathway | 66 |
antitumour response | 66 |
mblassociated serine | 66 |
pseudomonas aeruginosa | 66 |
ficolin ml | 66 |
different lab | 66 |
variant tumour | 66 |
mg bd | 66 |
ethyl pyruvate | 66 |
hepatocellular carcinoma | 66 |
macrophages elicited | 66 |
zone macrophages | 66 |
microbial surfaces | 66 |
polymerase chain | 66 |
homing cutaneous | 66 |
also observed | 66 |
may become | 66 |
peptide epitopes | 66 |
sentinel nodes | 66 |
database solution | 66 |
enriched ann | 66 |
plasma svegf | 66 |
hla supertype | 66 |
allergen carriers | 66 |
lymphocyteassociated antigen | 66 |
host immune | 66 |
sarcoid origin | 66 |
generation anns | 66 |
microarrays will | 66 |
unstimulated cd | 66 |
novel allergen | 66 |
rich data | 66 |
abdominal pain | 66 |
mediated opsonophagocytosis | 66 |
pulmonary tb | 66 |
qbc peptides | 66 |
masp activity | 66 |
mammalian cytokine | 66 |
laboratory notebooks | 66 |
highthroughput global | 66 |
invertebrate pattern | 66 |
transduced cell | 66 |
nonsentinel lymph | 66 |
affect nk | 66 |
boost vaccinations | 66 |
culture medium | 66 |
tnf blockade | 66 |
svegfr release | 66 |
containing ic | 66 |
preoperative mbl | 66 |
tumour extract | 66 |
blood leucocytes | 66 |
specific nucleotidyl | 66 |
hemorrhagic shock | 66 |
obtain tumour | 66 |
clinical data | 66 |
cutaneous lymphocyteassociated | 66 |
mbl concentration | 66 |
active site | 65 |
iav infection | 65 |
clinical course | 65 |
data show | 65 |
immunodeficiency virus | 65 |
free radical | 65 |
inhibitory effects | 65 |
study included | 65 |
may indicate | 65 |
also induces | 65 |
ob gyn | 64 |
pulmonary hypertension | 64 |
vaccinia virus | 64 |
inflammatory activity | 64 |
using elisa | 64 |
alveolar epithelial | 64 |
activity may | 64 |
previously demonstrated | 64 |
healthy control | 64 |
commonly used | 64 |
increased susceptibility | 64 |
kinase activity | 64 |
healthy subjects | 63 |
sertoli cells | 63 |
oleic acid | 63 |
antibody responses | 63 |
juvenile idiopathic | 63 |
five patients | 63 |
cells play | 63 |
time course | 63 |
differential expression | 63 |
every hours | 63 |
antibody response | 63 |
three groups | 63 |
enzyme activity | 63 |
cardiac surgery | 63 |
selectin expression | 63 |
coronary artery | 63 |
study group | 63 |
expression level | 63 |
red blood | 63 |
idiopathic arthritis | 62 |
tumor growth | 62 |
may represent | 62 |
bei patienten | 62 |
also play | 62 |
largely unknown | 62 |
cord blood | 62 |
protective role | 62 |
study design | 62 |
regulatory role | 62 |
potential therapeutic | 62 |
mediated immune | 62 |
ovarian cancer | 62 |
dna binding | 62 |
cells expressing | 62 |
four different | 61 |
costimulatory molecules | 61 |
cellular response | 61 |
cytokine expression | 61 |
novel coronavirus | 61 |
estrogen receptor | 61 |
first line | 61 |
reporter gene | 61 |
inflammatory reaction | 61 |
group ii | 61 |
induced inflammatory | 61 |
levels may | 61 |
compared using | 61 |
hours following | 61 |
blood monocytes | 60 |
high degree | 60 |
studies revealed | 60 |
inflammatory gene | 60 |
angiotensin ii | 60 |
cell lymphoma | 60 |
may serve | 60 |
protein kinases | 60 |
may affect | 60 |
target genes | 60 |
kg body | 60 |
th responses | 60 |
environmental factors | 60 |
binding sites | 60 |
higher risk | 60 |
two types | 60 |
human endothelial | 60 |
well known | 60 |
fully understood | 60 |
microarray analysis | 60 |
treated mice | 60 |
prospective study | 59 |
higher concentration | 59 |
showed significant | 59 |
lipid rafts | 59 |
much higher | 59 |
patient groups | 59 |
human disease | 59 |
cell functions | 59 |
kg min | 59 |
family history | 59 |
two major | 59 |
statistical significance | 59 |
th cytokines | 59 |
matched controls | 59 |
severe cases | 59 |
intercellular adhesion | 59 |
recent years | 59 |
full length | 59 |
data provide | 59 |
data demonstrate | 59 |
cell carcinoma | 59 |
studies suggest | 58 |
death domain | 58 |
also expressed | 58 |
plasma concentrations | 58 |
studies showed | 58 |
shock protein | 58 |
systematic review | 58 |
prostate cancer | 58 |
inflammatory processes | 58 |
one hand | 58 |
using different | 58 |
evidence indicates | 58 |
proteolytic cleavage | 58 |
direct effect | 58 |
patients received | 58 |
significant correlation | 58 |
renal disease | 58 |
lactate dehydrogenase | 58 |
patients admitted | 57 |
primary human | 57 |
host response | 57 |
also evaluated | 57 |
increasing evidence | 57 |
findings may | 57 |
odds ratio | 57 |
genetic background | 57 |
leydig cells | 57 |
inflammatory effect | 57 |
progenitor cells | 57 |
ii mhc | 57 |
basic protein | 57 |
analysis showed | 57 |
mm hg | 57 |
bei der | 57 |
physiological conditions | 56 |
buffered saline | 56 |
least one | 56 |
direct effects | 56 |
total protein | 56 |
gene polymorphisms | 56 |
mean arterial | 56 |
renal dysfunction | 56 |
immune function | 56 |
inkt cells | 56 |
promoter activity | 56 |
vascular smooth | 56 |
potential role | 56 |
acute renal | 56 |
treated cells | 56 |
oxide production | 56 |
cell mediated | 55 |
oxygen saturation | 55 |
mice lacking | 55 |
lung function | 55 |
tissue sections | 55 |
regression model | 55 |
mice infected | 55 |
myelin basic | 55 |
low level | 55 |
poorly understood | 55 |
mycobacterium tuberculosis | 55 |
infectious complications | 55 |
controlled trial | 55 |
recently demonstrated | 55 |
electron microscopy | 55 |
oxygen delivery | 55 |
using standard | 55 |
monocytes macrophages | 55 |
inflammatory markers | 55 |
antigen presenting | 55 |
oral cavity | 54 |
university medical | 54 |
retrospective study | 54 |
ii score | 54 |
growth restriction | 54 |
may explain | 54 |
highly significant | 54 |
cell populations | 54 |
body temperature | 54 |
induced acute | 54 |
cell development | 54 |
family members | 54 |
mediated inflammatory | 54 |
also used | 54 |
united kingdom | 54 |
synthetic peptides | 54 |
skin lesions | 54 |
dendritic cell | 54 |
human immunodeficiency | 54 |
cell degranulation | 54 |
clinical response | 54 |
one hour | 54 |
hormone receptors | 54 |
ms ms | 54 |
dawley rats | 54 |
inflammatory cell | 54 |
experiments showed | 54 |
antigen expression | 53 |
hek cells | 53 |
cellular stress | 53 |
brain barrier | 53 |
provide new | 53 |
mononuclear phagocytes | 53 |
bacterial infection | 53 |
directed mutagenesis | 53 |
signalling pathways | 53 |
th immune | 53 |
umbilical cord | 53 |
activation syndrome | 53 |
results may | 53 |
gastric mucosa | 53 |
group compared | 53 |
control mice | 53 |
related proteins | 53 |
trophoblast cells | 53 |
biologically active | 53 |
derived dendritic | 53 |
hsv infection | 53 |
preterm delivery | 53 |
will also | 53 |
und der | 53 |
bacterial infections | 52 |
stimulatory effect | 52 |
higher incidence | 52 |
endothelial dysfunction | 52 |
signal peptide | 52 |
positive bacteria | 52 |
lps stimulation | 52 |
nude mice | 52 |
recently reported | 52 |
preterm birth | 52 |
surgical procedures | 52 |
mechanically ventilated | 52 |
nutritional status | 52 |
ion channels | 52 |
xanthine oxidase | 52 |
ii expression | 52 |
clinical features | 52 |
blood sample | 52 |
helicobacter pylori | 52 |
umbilical vein | 52 |
ulcerative colitis | 52 |
severe disease | 52 |
collagen type | 52 |
connective tissue | 52 |
phase proteins | 52 |
patients suffering | 51 |
new therapeutic | 51 |
intravascular coagulation | 51 |
independent manner | 51 |
molecules involved | 51 |
seven days | 51 |
weight gain | 51 |
may improve | 51 |
tlr expression | 51 |
blood gases | 51 |
confocal microscopy | 51 |
observation period | 51 |
disease progression | 51 |
reduced il | 51 |
blood loss | 51 |
higher level | 51 |
sars patients | 51 |
metabolic acidosis | 51 |
transduction pathways | 51 |
still unclear | 51 |
blood vessels | 51 |
inflammatory properties | 51 |
lung disease | 50 |
signalling pathway | 50 |
useful tool | 50 |
low dose | 50 |
fat diet | 50 |
vg vd | 50 |
toxic effects | 50 |
time point | 50 |
positively charged | 50 |
coupled receptors | 50 |
informed consent | 50 |
low concentrations | 50 |
type diabetic | 50 |
lung carcinoma | 50 |
cells might | 50 |
therapeutic target | 50 |
time rt | 50 |
first hours | 50 |
necrotizing enterocolitis | 50 |
mechanisms involved | 50 |
wildtype mice | 50 |
phase i | 50 |
elisa method | 50 |
laser scanning | 50 |
alternative pathway | 50 |
receptor agonist | 50 |
menstrual cycle | 50 |
healthy human | 50 |
stromal cells | 49 |
considered statistically | 49 |
laboratory data | 49 |
early stage | 49 |
salivary glands | 49 |
immune reaction | 49 |
last decade | 49 |
bacterial translocation | 49 |
infl ammation | 49 |
nlrp inflammasome | 49 |
wistar rats | 49 |
allergic reactions | 49 |
cell sorting | 49 |
human umbilical | 49 |
united states | 49 |
intestinal inflammation | 49 |
different groups | 49 |
infection may | 49 |
genomic dna | 49 |
important implications | 49 |
cells increased | 49 |
tissue samples | 48 |
mhc ii | 48 |
germinal centers | 48 |
acute infection | 48 |
proteins may | 48 |
vast majority | 48 |
independent pathways | 48 |
sepsis syndrome | 48 |
differences among | 48 |
tumor suppressor | 48 |
tnf secretion | 48 |
marker cd | 48 |
mice showed | 48 |
every weeks | 48 |
structurally related | 48 |
cardiac index | 48 |
patients infected | 48 |
important roles | 48 |
genetic predisposition | 48 |
blood sampling | 48 |
gas exchange | 48 |
platelet aggregation | 48 |
adult horses | 48 |
cytokine il | 48 |
heart disease | 48 |
surfactant protein | 48 |
inflammatory stimuli | 48 |
containing proteins | 48 |
inhibits apoptosis | 48 |
stage renal | 48 |
surface antigen | 48 |
secondary antibody | 48 |
present results | 48 |
activation via | 48 |
specific primers | 47 |
different species | 47 |
molecular biology | 47 |
also examined | 47 |
disseminated intravascular | 47 |
proliferative response | 47 |
high level | 47 |
death receptor | 47 |
complex i | 47 |
severe malaria | 47 |
circulating levels | 47 |
inflammatory skin | 47 |
treated animals | 47 |
preterm labor | 47 |
pulmonary edema | 47 |
pulmonary vascular | 47 |
circulating neutrophils | 47 |
results also | 47 |
lactate levels | 47 |
times lower | 47 |
initial phase | 47 |
response rates | 47 |
even though | 47 |
demyelinating disease | 47 |
different cell | 47 |
mit einer | 47 |
induced lung | 47 |
different molecular | 47 |
viral load | 47 |
ripk kinase | 47 |
central venous | 47 |
human colon | 47 |
peritoneal cavity | 47 |
study suggest | 47 |
dramatically increased | 47 |
parenteral nutrition | 47 |
acute viral | 47 |
left ventricular | 47 |
gastrointestinal mucosa | 46 |
human cd | 46 |
negative regulators | 46 |
pregnant rats | 46 |
general hospital | 46 |
data presented | 46 |
squamous cell | 46 |
recent study | 46 |
cpg dna | 46 |
longitudinal study | 46 |
case report | 46 |
placebo group | 46 |
almost exclusively | 46 |
host cells | 46 |
increased il | 46 |
highly pathogenic | 46 |
respiratory disease | 46 |
interferon gamma | 46 |
associated antigen | 46 |
molecular mass | 46 |
may account | 46 |
lung epithelial | 46 |
human myometrium | 46 |
colorectal carcinoma | 46 |
inhibitory activity | 46 |
renal function | 46 |
interferon production | 46 |
pulmonary disease | 46 |
derived dcs | 46 |
glucose tolerance | 46 |
clinical outcome | 46 |
increased cell | 46 |
cohort study | 46 |
may allow | 46 |
chemokine expression | 46 |
host disease | 46 |
protein production | 46 |
serum total | 45 |
patients died | 45 |
randomly selected | 45 |
coagulation factor | 45 |
nuclear receptor | 45 |
glucose levels | 45 |
may modulate | 45 |
significantly inhibited | 45 |
thymidine incorporation | 45 |
liver cirrhosis | 45 |
ligand interactions | 45 |
study involved | 45 |
two doses | 45 |
critical illness | 45 |
regulated genes | 45 |
normal individuals | 45 |
five different | 45 |
inflammatory mechanisms | 45 |
also capable | 45 |
low expression | 45 |
virus infections | 45 |
control cells | 45 |
lymphocytic choriomeningitis | 45 |
significant changes | 45 |
days pi | 45 |
matched healthy | 45 |
human beings | 45 |
cells treated | 45 |
scanning microscopy | 45 |
cellular mechanisms | 45 |
also showed | 45 |
mg daily | 45 |
molecular mimicry | 45 |
therapeutic strategies | 45 |
tidal volume | 45 |
lower doses | 45 |
cytotoxic cd | 45 |
membrane potential | 45 |
using human | 45 |
six hours | 45 |
different concentrations | 44 |
study period | 44 |
days post | 44 |
tlr ligands | 44 |
previous study | 44 |
asthmatic patients | 44 |
tnf receptors | 44 |
stress response | 44 |
induced tnf | 44 |
subsequent activation | 44 |
significant association | 44 |
nadph oxidase | 44 |
specific cellular | 44 |
mammalian cell | 44 |
studies indicated | 44 |
gland tissue | 44 |
high fat | 44 |
production induced | 44 |
whether il | 44 |
coding regions | 44 |
skin disease | 44 |
culture media | 44 |
cancer immunotherapy | 44 |
also significantly | 44 |
elisa technique | 44 |
valuable tool | 44 |
blood levels | 44 |
salivary gland | 44 |
immune dysregulation | 44 |
enzyme activities | 44 |
receptor signaling | 44 |
direct contact | 44 |
shock proteins | 44 |
prospective studies | 44 |
induced ifn | 44 |
using gene | 44 |
sex hormone | 44 |
und die | 44 |
blood glucose | 44 |
mitochondrial membrane | 44 |
lower risk | 44 |
bovine serum | 44 |
routine clinical | 44 |
weeks gestation | 44 |
receptor signalling | 43 |
well tolerated | 43 |
early stages | 43 |
animal studies | 43 |
gram negative | 43 |
gene family | 43 |
induced macrophage | 43 |
human epidermal | 43 |
signal intensity | 43 |
important regulator | 43 |
inflammatory disorders | 43 |
human dendritic | 43 |
lower dose | 43 |
leading causes | 43 |
leptin receptor | 43 |
surface plasmon | 43 |
mice treated | 43 |
intestinal flora | 43 |
decreased significantly | 43 |
soluble tnf | 43 |
studies suggested | 43 |
type immune | 43 |
remains unclear | 43 |
zinc supplementation | 43 |
bacterial antigens | 43 |
plasmon resonance | 43 |
diabetic nephropathy | 43 |
significantly better | 43 |
occurs via | 43 |
immunological responses | 43 |
allow us | 43 |
peripheral cd | 43 |
median age | 43 |
translational modification | 43 |
increased release | 43 |
single dose | 43 |
gene transcription | 43 |
immunol doi | 43 |
acquired immunity | 43 |
one patients | 43 |
malignant transformation | 43 |
molecular medicine | 43 |
including il | 43 |
assessed using | 43 |
active molecules | 43 |
cd may | 43 |
hla class | 43 |
survival time | 43 |
individual patients | 43 |
proteins involved | 42 |
pcr technique | 42 |
elisa kits | 42 |
respiratory viruses | 42 |
induced cell | 42 |
levels increased | 42 |
binding studies | 42 |
da rats | 42 |
large intestinal | 42 |
different proteins | 42 |
mean tnf | 42 |
strongly inhibited | 42 |
urinary bladder | 42 |
also indicated | 42 |
killer cells | 42 |
ige levels | 42 |
treated group | 42 |
colony stimulating | 42 |
liquid chromatography | 42 |
positive control | 42 |
rheumatic diseases | 42 |
significant role | 42 |
specific ctl | 42 |
unstimulated cells | 42 |
room temperature | 42 |
acid sequence | 42 |
therapeutic potential | 42 |
induced inflammation | 42 |
studied whether | 42 |
nuclear translocation | 42 |
associated immune | 42 |
various cancer | 42 |
induce il | 42 |
mannose receptor | 42 |
using non | 42 |
adenosine receptors | 42 |
leukocyte adhesion | 42 |
fetal membranes | 42 |
confocal laser | 42 |
rna isolated | 42 |
fl uid | 42 |
median values | 42 |
potential risk | 42 |
cultured human | 42 |
inflammatory conditions | 42 |
directly induce | 42 |
phase ii | 42 |
even higher | 42 |
studies involving | 42 |
histamine release | 42 |
plasminogen activator | 41 |
biological properties | 41 |
play important | 41 |
infected fetuses | 41 |
induce expression | 41 |
barrier function | 41 |
female patients | 41 |
blood cd | 41 |
express il | 41 |
induced significant | 41 |
beneficial effect | 41 |
specific ifn | 41 |
regulatory cytokines | 41 |
particularly important | 41 |
health effects | 41 |
complement factor | 41 |
dna methylation | 41 |
blood stem | 41 |
androgen receptor | 41 |
medical school | 41 |
cov infection | 41 |
factors like | 41 |
specific immunity | 41 |
pharmakologie und | 41 |
important part | 41 |
promote cell | 41 |
significant expression | 41 |
infl uence | 41 |
important regulators | 41 |
injected i | 41 |
health care | 41 |
cardiovascular diseases | 41 |
cell infiltration | 41 |
two distinct | 41 |
binding region | 41 |
molecular mechanism | 41 |
medical microbiology | 41 |
borrelia burgdorferi | 41 |
bacterial products | 41 |
reproductive tract | 41 |
immune modulation | 41 |
acid sphingomyelinase | 41 |
different diseases | 41 |
eicosanoid synthesis | 41 |
also exist | 41 |
standard deviation | 41 |
various times | 41 |
bead array | 41 |
ischemic stroke | 41 |
wide spectrum | 41 |
intraperitoneally injected | 41 |
surface receptors | 41 |
plasma protein | 41 |
exclusion chromatography | 41 |
chronic obstructive | 41 |
kb activation | 41 |
mice bearing | 41 |
cutaneous lymphocyte | 41 |
apoptotic signal | 41 |
autoantibody production | 41 |
cellular interactions | 41 |
essential role | 41 |
light microscope | 41 |
acts via | 41 |
studies using | 41 |
specific ige | 41 |
trypanosoma cruzi | 41 |
mediated disease | 41 |
antigenpresenting cells | 41 |
producing cells | 41 |
mass index | 41 |
like structure | 41 |
ii mrna | 41 |
monocytic cell | 41 |
much greater | 41 |
psoriasis patients | 40 |
ii cells | 40 |
multivariate regression | 40 |
similar effect | 40 |
soluble antigens | 40 |
severe influenza | 40 |
increased cd | 40 |
may potentially | 40 |
host cell | 40 |
epitope specificity | 40 |
suppressor cells | 40 |
binding motif | 40 |
induced cd | 40 |
million people | 40 |
vaccine design | 40 |
recombinant fusion | 40 |
multiple trauma | 40 |
address whether | 40 |
systemic vascular | 40 |
mean ae | 40 |
adverse events | 40 |
high mortality | 40 |
cytotoxic activity | 40 |
germ cells | 40 |
sequence similarity | 40 |
increasing age | 40 |
growth arrest | 40 |
choriocarcinoma cell | 40 |
responsive genes | 40 |
experimental animals | 40 |
among patients | 40 |
investigating whether | 40 |
epithelial tissues | 40 |
antioxidant status | 40 |
often present | 40 |
several months | 40 |
proliferation assays | 40 |
immunosorbent assay | 40 |
minor salivary | 40 |
induced higher | 40 |
breast carcinoma | 40 |
inflammatory signal | 40 |
serum il | 40 |
mean values | 40 |
fluorescence microscopy | 40 |
complex class | 40 |
cells via | 40 |
molecules cd | 40 |
inducible expression | 40 |
potassium channels | 40 |
matrix metalloproteinases | 40 |
molecule cd | 40 |
house dust | 40 |
severely impaired | 40 |
cancer cases | 40 |
double staining | 40 |
including rheumatoid | 40 |
like activity | 40 |
phase reactant | 40 |
exact role | 40 |
directly interact | 40 |
cells proliferate | 40 |
resistance mechanisms | 40 |
cytotoxic effect | 40 |
control study | 40 |
lavage fluid | 40 |
six times | 40 |
following treatment | 40 |
might result | 40 |
will present | 40 |
transcriptional activity | 40 |
hiv infection | 39 |
different types | 39 |
infiltrating macrophages | 39 |
alternative activation | 39 |
least months | 39 |
common cold | 39 |
susceptible mice | 39 |
aluminium hydroxide | 39 |
many others | 39 |
remained largely | 39 |
microarray technology | 39 |
induced colitis | 39 |
classically activated | 39 |
mouse macrophage | 39 |
cytometric bead | 39 |
high grade | 39 |
autologous monocytes | 39 |
cytolytic activity | 39 |
mhc molecules | 39 |
higher blood | 39 |
tnf alpha | 39 |
also inhibit | 39 |
total ige | 39 |
antibody production | 39 |
fed either | 39 |
effective method | 39 |
mapk pathway | 39 |
molecules expressed | 39 |
mean time | 39 |
three times | 39 |
vivo studies | 39 |
sars cov | 39 |
regulatory cd | 39 |
evidence suggests | 39 |
binding affinities | 39 |
exchange chromatography | 39 |
different tlr | 39 |
remained unchanged | 39 |
cardiac function | 39 |
matrix metalloproteinase | 39 |
regulatory phenotype | 39 |
minor surgery | 39 |
ist die | 39 |
memory response | 39 |
platelet activation | 39 |
magnetic beads | 39 |
increasing interest | 39 |
infectious peritonitis | 39 |
manganese superoxide | 39 |
recently established | 39 |
signaling molecules | 39 |
tight junction | 39 |
complement pathways | 39 |
human cytokines | 39 |
immune activation | 39 |
mediated anti | 39 |
cytotoxic activities | 39 |
quantitative rt | 39 |
mitochondrial enzyme | 39 |
significantly downregulated | 39 |
exhibited similar | 39 |
among many | 39 |
curative treatment | 39 |
expression occurs | 39 |
identify patients | 39 |
tested positive | 39 |
different pathways | 39 |
remain largely | 39 |
among strains | 39 |
also increased | 39 |
wide variety | 39 |
highly expressed | 39 |
epidermal growth | 39 |
induce specific | 39 |
enzymatic activity | 39 |
pao fio | 39 |
effects observed | 39 |
many studies | 39 |
induced activation | 39 |
decreased expression | 39 |
th effector | 39 |
sensitive detection | 39 |
und toxikologie | 39 |
cesarean section | 39 |
three proteins | 38 |
der patienten | 38 |
adjuvant properties | 38 |
linked glycosylation | 38 |
biological activities | 38 |
probiotic bacteria | 38 |
activated macrophage | 38 |
using cytokine | 38 |
inhibited il | 38 |
stimulated pbmc | 38 |
microbial components | 38 |
vascular lesions | 38 |
phagocytic cell | 38 |
immunomodulatory effect | 38 |
dimensional structure | 38 |
lymphocyte infiltration | 38 |
food intake | 38 |
type lectin | 38 |
acute inflammatory | 38 |
activated complement | 38 |
expanded cd | 38 |
tight junctions | 38 |
total igg | 38 |
week intervals | 38 |
normal range | 38 |
experimental model | 38 |
igm anti | 38 |
greater effect | 38 |
crc patients | 38 |
probiotic strains | 38 |
based vaccines | 38 |
condition characterized | 38 |
mobility group | 38 |
cell balance | 38 |
patients experiencing | 38 |
obstructive pulmonary | 38 |
inflammatory genes | 38 |
analysis reveals | 38 |
airway pressure | 38 |
study evaluated | 38 |
produce large | 38 |
mucosal injury | 38 |
intestinal mucosa | 38 |
complement factors | 38 |
proteins showed | 38 |
derived peptide | 38 |
evolutionary conserved | 38 |
signalling molecule | 38 |
kupffer cells | 38 |
different bacterial | 38 |
viral rna | 38 |
mechanisms behind | 38 |
many immune | 38 |
gastrointestinal flora | 38 |
small size | 38 |
induced upregulation | 38 |
serum tnf | 38 |
clinical manifestations | 38 |
blue dye | 38 |
per kg | 38 |
cell lung | 38 |
adjuvant effect | 38 |
proteins using | 38 |
specifically bind | 38 |
exact mechanisms | 38 |
microvascular endothelial | 38 |
represents one | 38 |
cell numbers | 38 |
apoptosis proteins | 38 |
might contribute | 38 |
reduced mhc | 38 |
following acute | 38 |
coli lipopolysaccharide | 38 |
uric acid | 38 |
trypanosoma brucei | 38 |
map gene | 38 |
dna laddering | 38 |
treg cell | 38 |
macrophage culture | 38 |
part mediated | 38 |
scientific community | 38 |
cytotoxic effects | 38 |
peptide pools | 38 |
gene families | 38 |
lps challenge | 38 |
diseases caused | 38 |
study showed | 38 |
female mice | 38 |
induced cytokine | 38 |
primary function | 38 |
protein purification | 38 |
developed using | 38 |
priming effect | 38 |
will affect | 38 |
usp expression | 38 |
receptor binding | 38 |
tcr repertoire | 38 |
sequence information | 38 |
completely abrogated | 38 |
sle patients | 38 |
similar results | 38 |
neutrophil infiltration | 38 |
dengue virus | 38 |
mucosal barrier | 38 |
two members | 37 |
first generation | 37 |
total number | 37 |
mitochondrial dysfunction | 37 |
equally well | 37 |
covalent coupling | 37 |
transcriptional regulation | 37 |
cell wall | 37 |
epithelial apoptosis | 37 |
showed significantly | 37 |
epithelial layers | 37 |
rheumatic disease | 37 |
clinical context | 37 |
greater proportion | 37 |
collected immediately | 37 |
dna microarrays | 37 |
double kos | 37 |
differentially affect | 37 |
mammalian host | 37 |
growth advantage | 37 |
early phase | 37 |
responses following | 37 |
median serum | 37 |
mg per | 37 |
protein induced | 37 |
oligoadenylate synthetase | 37 |
thereby allowing | 37 |
standard assays | 37 |
specific iga | 37 |
terminal amino | 37 |
vaccine candidates | 37 |
uncomplicated malaria | 37 |
first decade | 37 |
capsid proteins | 37 |
lps also | 37 |
size exclusion | 37 |
doublestranded rna | 37 |
murine monoclonal | 37 |
higher mrna | 37 |
selectin gene | 37 |
postoperative period | 37 |
reporter genes | 37 |
fetal brain | 37 |
significantly correlated | 37 |
soluble receptors | 37 |
monocytes differentiate | 37 |
crucial step | 37 |
maturation marker | 37 |
small cell | 37 |
basement membrane | 37 |
cells positive | 37 |
cytokines increased | 37 |
stress level | 37 |
arginase activity | 37 |
bile acid | 37 |
first steps | 37 |
cell size | 37 |
optimal stimulation | 37 |
adenosine receptor | 37 |
system consists | 37 |
takes place | 37 |
neurodegenerative diseases | 37 |
network model | 37 |
within days | 37 |
anaphylactic reactions | 37 |
may fail | 37 |
human macrophages | 37 |
partially rescued | 37 |
different antigens | 37 |
cell density | 37 |
human nk | 37 |
either ifn | 37 |
ige epitopes | 37 |
dependent proliferation | 37 |
interstitial lung | 37 |
animals exhibited | 37 |
induce apoptotic | 37 |
cell responsiveness | 37 |
remained unaltered | 37 |
streptococcus pyogenes | 37 |
normal functions | 37 |
people worldwide | 37 |
adoptive immunotherapy | 37 |
via effects | 37 |
tumour antigens | 37 |
stained cells | 37 |
rat serum | 37 |
lactobacillus plantarum | 37 |
proinflammatory chemokines | 37 |
cell ifn | 37 |
strong th | 37 |
atopic eczema | 37 |
anthropometric measurements | 37 |
mg mg | 37 |
ultrasound stimulation | 37 |
cells stimulated | 37 |
work provides | 37 |
higher concentrations | 37 |
oxidative damage | 37 |
mutation leads | 37 |
clinical characteristics | 37 |
cytokine receptors | 37 |
glial cells | 37 |
peptides corresponding | 37 |
superfamily members | 37 |
feline infectious | 37 |
maximum tnf | 36 |
immunomodulatory cytokines | 36 |
observed reduction | 36 |
th dichotomy | 36 |
monocytes produced | 36 |
neutralizing antibodies | 36 |
stress model | 36 |
ms sera | 36 |
essential processes | 36 |
human mhc | 36 |
research laboratories | 36 |
demonstrate whether | 36 |
complexes activate | 36 |
arthritogenic properties | 36 |
recurrent inflammation | 36 |
care units | 36 |
cell suspensions | 36 |
better understanding | 36 |
evaluated using | 36 |
findings identify | 36 |
femoral head | 36 |
identified five | 36 |
immunological characteristics | 36 |
endotoxic shock | 36 |
adaptor protein | 36 |
streptococcal pyrogenic | 36 |
including tnf | 36 |
isotype switching | 36 |
mammary epithelial | 36 |
docking site | 36 |
protein concentration | 36 |
find new | 36 |
important effector | 36 |
clinic visits | 36 |
experimental settings | 36 |
levels comparable | 36 |
soluble fraction | 36 |
also applied | 36 |
expressed significantly | 36 |
associated molecules | 36 |
pathway components | 36 |
purified monocytes | 36 |
women undergoing | 36 |
complex mixtures | 36 |
present work | 36 |
isotonic saline | 36 |
pfbm cells | 36 |
cell immunoglobulin | 36 |
statistically analysed | 36 |
several cases | 36 |
experimental models | 36 |
lung fibrosis | 36 |
oxygen consumption | 36 |
three patients | 36 |
ml range | 36 |
immunological memory | 36 |
earlier work | 36 |
whereas others | 36 |
atopic dermatitis | 36 |
demonstrate binding | 36 |
intracellular signaling | 36 |
whether vitamin | 36 |
facs analysis | 36 |
given subcutaneously | 36 |
dna repair | 36 |
repeated times | 36 |
suitable model | 36 |
terminal regions | 36 |
various species | 36 |
detected among | 36 |
acid change | 36 |
major type | 36 |
polymorphism results | 36 |
critically important | 36 |
infection will | 36 |
found mainly | 36 |
asthma control | 36 |
sars coronavirus | 36 |
specific marker | 36 |
idiotypic antibody | 36 |
reduced expansion | 36 |
protein antigens | 36 |
therapeutic approaches | 36 |
esrd patients | 36 |
nonspecific immune | 36 |
markedly suppressed | 36 |
recombinant form | 36 |
coronavirus infection | 36 |
incidence rate | 36 |
many countries | 36 |
immunomagnetic beads | 36 |
independent way | 36 |
percent predicted | 36 |
transcriptional regulators | 36 |
cells using | 36 |
metastatic cancer | 36 |
preliminary data | 36 |
macrophages induce | 36 |
increased local | 36 |
proteins known | 36 |
lung mucosa | 36 |
key transcriptional | 36 |
modulate cancer | 36 |
effects include | 36 |
dysfunction may | 36 |
similar patterns | 36 |
pathogenesis remains | 36 |
antigens derived | 36 |
urea levels | 36 |
variants may | 36 |
mainly cd | 36 |
markers associated | 36 |
second generation | 36 |
buffy coats | 36 |
borrelia spirochetes | 36 |
tunel assays | 36 |
mit einem | 36 |
may associate | 36 |
ldh release | 36 |
cell dna | 36 |
kg bw | 36 |
mice demonstrate | 36 |
year old | 36 |
myeloid dc | 36 |
using abc | 36 |
approximately kda | 36 |
systemic immunity | 36 |
including breast | 36 |
assay sensitivity | 36 |
antitumour effects | 36 |
supplementation increased | 36 |
substantial differences | 36 |
immunostimulatory effects | 36 |
depends largely | 36 |
single cell | 36 |
like lesions | 36 |
inhibitory receptor | 36 |
may point | 36 |
cell membranes | 36 |
middle east | 36 |
cervical ripening | 36 |
pronounced differences | 36 |
early diagnosis | 36 |
cells circulating | 36 |
fine mapping | 36 |
expression without | 36 |
quantitated using | 36 |
nonlymphoid cells | 36 |
exclusively expressed | 36 |
epitope mapping | 36 |
porcine reproductive | 36 |
time periods | 36 |
interacting protein | 36 |
effectively controlled | 36 |
gel permeation | 36 |
term prognosis | 36 |
immunosorbent assays | 36 |
sertoli cell | 36 |
clonal deletion | 36 |
induce interleukin | 36 |
insulin sensitivity | 36 |
identify candidate | 36 |
lethally irradiated | 36 |
ep treatment | 35 |
type iii | 35 |
influenza viruses | 35 |
upper airways | 35 |
human parvovirus | 35 |
using mutagenesis | 35 |
following weeks | 35 |
tlr pathways | 35 |
parallel experiment | 35 |
remains obscure | 35 |
dramatically induced | 35 |
hbv infection | 35 |
cardiac arrest | 35 |
induced regulatory | 35 |
perform better | 35 |
found frequently | 35 |
peptide mhc | 35 |
require confirmation | 35 |
specific ab | 35 |
network interactions | 35 |
regulatory factor | 35 |
major human | 35 |
alkaline phosphatase | 35 |
vein endothelial | 35 |
two hours | 35 |
basal cell | 35 |
metabolic stress | 35 |
receptor activation | 35 |
stimulated expression | 35 |
performed significantly | 35 |
investigated serum | 35 |
stimulate expression | 35 |
ko phenotype | 35 |
phenotype may | 35 |
liver tissue | 35 |
stimulation assay | 35 |
systemic th | 35 |
expressed lower | 35 |
now report | 35 |
proper th | 35 |
threefold higher | 35 |
chloride channels | 35 |
complement resistance | 35 |
maintaining homeostasis | 35 |
permeation chromatography | 35 |
poor survival | 35 |
differentially activate | 35 |
wide scan | 35 |
achieved mainly | 35 |
recently generated | 35 |
molecules hla | 35 |
autoantibodies directed | 35 |
several inhibitors | 35 |
acutely infected | 35 |
flora including | 35 |
urea concentrations | 35 |
chikungunya virus | 35 |
response revealed | 35 |
monoclonal igm | 35 |
receptor decreased | 35 |
free university | 35 |
malassezia sympodialis | 35 |
position showed | 35 |
revealed five | 35 |
ion exchange | 35 |
small molecule | 35 |
burgdorferi sensu | 35 |
three structurally | 35 |
strong cytokine | 35 |
safer alternative | 35 |
coli infections | 35 |
hinge region | 35 |
corresponding recombinant | 35 |
normal skin | 35 |
phenotypic change | 35 |
inactivated serum | 35 |
human hla | 35 |
mortality may | 35 |
coculture system | 35 |
successfully applied | 35 |
low doses | 35 |
lower surface | 35 |
reverse transcription | 35 |
well plates | 35 |
produce type | 35 |
see whether | 35 |
aarhus university | 35 |
approximately months | 35 |
resonance analysis | 35 |
asthmatic lung | 35 |
culture cell | 35 |
status might | 35 |
also demonstrate | 35 |
still significant | 35 |
bacteria induced | 35 |
extracellular signal | 35 |
profound impact | 35 |
growth hormone | 35 |
plasmacytoid dc | 35 |
turn results | 35 |
humeral immunity | 35 |
cells also | 35 |
potential vaccine | 35 |
inflammatory reactions | 35 |
immobilization strategies | 35 |
patients expressed | 35 |
acute inflammation | 35 |
soluble cd | 35 |
subsequently determined | 35 |
two additional | 35 |
lysine residues | 35 |
sugar metabolism | 35 |
synovial fluid | 35 |
chain fv | 35 |
exact knowledge | 35 |
autoimmune condition | 35 |
mucosa samples | 35 |
specific immunotherapy | 35 |
adjuvant potential | 35 |
novel affinity | 35 |
early pregnancy | 35 |
reticulum stress | 35 |
also shown | 35 |
increased cytotoxicity | 35 |
around one | 35 |
computer program | 35 |
derived murine | 35 |
disulfide bond | 35 |
proteins used | 35 |
postoperative infection | 35 |
involving macrophages | 35 |
significantly potentiated | 35 |
different surgical | 35 |
clinical malaria | 35 |
hela cells | 35 |
candidate autoantigen | 35 |
ro ssa | 35 |
subsequent challenge | 35 |
gradient gel | 35 |
generally low | 35 |
excellent functional | 35 |
construct based | 35 |
potent inhibitor | 35 |
mean percentage | 35 |
three days | 35 |
two recombinant | 35 |
patients lacking | 35 |
molecule ceramide | 35 |
grade iii | 35 |
will play | 35 |
disease atopic | 35 |
new vaccines | 35 |
current standard | 35 |
arthritic animals | 35 |
dcs compared | 35 |
unstimulated human | 35 |
one among | 35 |
tests will | 35 |
surviving bacteria | 35 |
undergoing periodic | 35 |
specific igm | 35 |
system allows | 35 |
potential cross | 35 |
effective treatment | 35 |
pcr methods | 35 |
way anova | 35 |
cell clonotypes | 35 |
high doses | 35 |
international data | 35 |
cell activity | 35 |
well established | 35 |
potential exists | 35 |
lung diseases | 35 |
lymphocyte population | 35 |
predicted epitopes | 35 |
gland development | 35 |
combined data | 35 |
also potentiated | 35 |
surface mhc | 35 |
lung lymph | 35 |
erk pathways | 35 |
cell signaling | 35 |
neuroectodermal origin | 35 |
volunteers using | 35 |
protective dna | 35 |
genes specific | 35 |
steady state | 35 |
coli infection | 35 |
yeast malassezia | 35 |
liver failure | 35 |
largely unchanged | 35 |
selected strains | 35 |
even lower | 35 |
whether gc | 35 |
alternative splicing | 35 |
enhanced ifn | 35 |
yersinia enterocolitica | 35 |
allergic individuals | 35 |
molecular structures | 35 |
colour flow | 35 |
mucosal sites | 35 |
five commercially | 35 |
simultaneous expression | 35 |
gain access | 35 |
comparing patients | 35 |
wt control | 35 |
components like | 35 |
diabetic vascular | 35 |
influenza infection | 35 |
alpha production | 35 |
capsular polysaccharide | 35 |
aureus strain | 35 |
novel molecule | 35 |
antigens within | 35 |
cell replication | 35 |
genetic polymorphisms | 35 |
tcm formulas | 35 |
gained increasing | 35 |
elevated anti | 35 |
directly applied | 35 |
foreign antigen | 35 |
standard statistical | 35 |
cytokines used | 35 |
purification procedure | 35 |
expression showed | 35 |
animals injected | 35 |
readily detectable | 35 |
cells acquire | 35 |
partially prevented | 35 |
angiotensin converting | 35 |
receiving long | 35 |
immunity via | 35 |
cytokine gene | 35 |
array screen | 35 |
cr release | 35 |
carbohydrate structures | 35 |
first demonstrate | 35 |
vitro experiments | 35 |
sympodialis allergen | 35 |
mainly induced | 35 |
human factor | 35 |
protein engineering | 35 |
mhc complex | 35 |
th day | 35 |
allergen extracts | 35 |
molecular repertoire | 34 |
colonic biopsies | 34 |
magnetically separated | 34 |
distinct possibility | 34 |
initiated activation | 34 |
overt nephropathy | 34 |
zeptomole range | 34 |
responses target | 34 |
cerebrospinal fluid | 34 |
cycle time | 34 |
simulated heliox | 34 |
induced phagocytosis | 34 |
recombinant pro | 34 |
different commensal | 34 |
isogenic serotype | 34 |
separated cd | 34 |
aerococcus viridans | 34 |
sweden belongs | 34 |
technique involving | 34 |
cell directly | 34 |
followed consecutively | 34 |
tick vector | 34 |
donors grown | 34 |
totally inhibited | 34 |
specific poly | 34 |
place high | 34 |
newly emerged | 34 |
standard cr | 34 |
considered significant | 34 |
results demonstrates | 34 |
control diet | 34 |
collected seven | 34 |
inhaled long | 34 |
high demands | 34 |
weeks fed | 34 |
extensive sequence | 34 |
mnsod needs | 34 |
investigated immunological | 34 |
binding efficiency | 34 |
local autoantibody | 34 |
technology will | 34 |
iga molecules | 34 |
reconstitution experiments | 34 |
short term | 34 |
five acutely | 34 |
considerable less | 34 |
increased mbl | 34 |
spontaneous cytotoxicity | 34 |
providing sensitive | 34 |
coupling strategies | 34 |
ncoder framework | 34 |
prevented sendai | 34 |
research activity | 34 |
deficient compared | 34 |
morphologically screened | 34 |
antibodies along | 34 |
pyrogenic exotoxin | 34 |
mounted hbsag | 34 |
mixtures occasionally | 34 |
identical genotypes | 34 |
inhibited kb | 34 |
around calving | 34 |
controlled based | 34 |
probes retained | 34 |
therefore examined | 34 |
degradation processes | 34 |
elevated mbl | 34 |
interactions trigger | 34 |
jak stat | 34 |
system occurs | 34 |
different coupling | 34 |
via four | 34 |
improve diseases | 34 |
pneumococci produce | 34 |
designated mala | 34 |
upregulated cd | 34 |
consistently low | 34 |
natural autoantibodies | 34 |
nonradioactive proliferation | 34 |
last immunization | 34 |
novozymes focuses | 34 |
inhaled corticosteroid | 34 |
tigr strain | 34 |
higher abca | 34 |
receptors seem | 34 |
supports used | 34 |
increasing dietary | 34 |
hbsag contains | 34 |
denaturing gradient | 34 |
include components | 34 |
constructed around | 34 |
gut mucosa | 34 |
juice urea | 34 |
second class | 34 |
immunologic similarity | 34 |
immununized mice | 34 |
asthma exacerbated | 34 |
mt correlates | 34 |
bacteria will | 34 |
clonotype mapping | 34 |
clinical symptoms | 34 |
litter size | 34 |
noncytopathic lymphocytic | 34 |
strains weak | 34 |
induction inhibited | 34 |
vastly predominant | 34 |
catalytic mechanism | 34 |
measurable proliferation | 34 |
physical examination | 34 |
thereby becoming | 34 |
inflammation involving | 34 |
tlr involved | 34 |
represent novel | 34 |
different peptide | 34 |
higher focus | 34 |
specifically induced | 34 |
enzyme complexes | 34 |
target antigens | 34 |
persistent normoalbuminuria | 34 |
skin via | 34 |
especially attracted | 34 |
atopic allergy | 34 |
significantly amplified | 34 |
genetically constructed | 34 |
roughly corresponding | 34 |
protein followed | 34 |
cytometry offers | 34 |
lower prostaglandin | 34 |
tnf levels | 34 |
antiviral enzymes | 34 |
assay described | 34 |
mt decreased | 34 |
mbl plays | 34 |
promoting function | 34 |
special focus | 34 |
eight exons | 34 |
levels independently | 34 |
increasing urea | 34 |
either seretide | 34 |
microorganisms seems | 34 |
investigated il | 34 |
nearly pure | 34 |
constitute part | 34 |
numerically higher | 34 |
expression mbl | 34 |
lymphocytes play | 34 |
sensitivity reaction | 34 |
heterohybridoma technique | 34 |
wt controls | 34 |
cd adim | 34 |
emerged clonotypes | 34 |
ectopic germinal | 34 |
immunity leads | 34 |